Philadelphia, PANCT01851694Now EnrollingIRB Ready

Cystic Fibrosis Clinical Trial in Philadelphia, PA

Access cutting-edge cystic fibrosis treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by University of Pennsylvania

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access cystic fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cystic fibrosis treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this cystic fibrosis clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Cystic Fibrosis Study in Philadelphia

In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear. The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients. Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups: * Cystic Fibrosis participants with normal glucose tolerance * Non-Cystic Fibrosis controls

Sponsor: University of Pennsylvania

Who Can Participate

Inclusion Criteria

Confirmed diagnosis of cystic fibrosis, defined by positive sweat test or CFTR mutation analysis according to CFF diagnostic criteria,
Age greater than or equal to 18y on date of consent
Pancreatic insufficiency
Recent OGTT consistent with Indeterminate-GT, IGT, CFRD w/o fasting hyperglycemia, or an established diagnosis of CFRD without fasting hyperglycemia
For female subjects, negative urine pregnancy test at enrollment. Control Subjects:
No history of cystic fibrosis.
Age ≥ 18y on date of consent.
Recent OGTT consistent with NGT.
For female subjects, negative urine pregnancy test at enrollment.

Exclusion Criteria

Established diagnosis of non-CF diabetes (i.e. T1D) or CFRD with fasting hyperglycemia (fasting glucose greater than126 mg/dL)
History of clinically symptomatic pancreatitis within last year
Prior lung or liver transplant
Severe CF liver disease, as defined by portal hypertension
Fundoplication-related dumping syndrome
Medical co-morbidities that are not CF-related or are unstable per investigator opinion (i.e. history of bleeding disorders, immunodeficiency)
Acute illness or changes in therapy (including antibiotics) within 6 weeks prior to study procedures
Treatment with oral or intravenous corticosteroids within 6 weeks of study
Hemoglobin less than10g/dL, within 90 days of Visit 1 or at Screening
Abnormal renal function, within 90 days of Visit 1 or at Screening; defined as Creatinine greater than 2x upper limit of normal (ULN) or potassium greater than 5.5mEq/L on non-hemolyzed specimen
Inability to perform study specific procedures (MMTT, GPA)
Subjects, who in study team opinion, may be non-compliant with study procedures. Control Subjects who will be exposed to GIP only:
History of clinically symptomatic pancreatitis.
History of liver disease.
History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject.
Hemoglobin \<10g/dL, within 90 days of GPA test or at Screening.
Abnormal renal function, within 90 days of GPA test or at Screening; defined as creatinine \> 2x upper limit of normal (ULN) or potassium \> 5.5mEq/L on non-hemolyzed specimen.
Inability to perform study specific procedures (MMTT, GPA).
subjects, who in study team opinion, may be non-compliant with study procedures.
elevation of serum amylase or lipase \> 1.5x ULN within 90 days of GPA test.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT01851694) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cystic Fibrosis Treatment Options in Philadelphia, PA

If you're searching for cystic fibrosis treatment options in Philadelphia, PA, this clinical trial (NCT01851694) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cystic fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cystic fibrosis clinical trials near you to find additional studies recruiting in your area.

More Cystic Fibrosis Trials in Philadelphia, PA

See all cystic fibrosis clinical trials recruiting in Philadelphia — not just this study.

Browse Cystic Fibrosis Trials in Philadelphia →

Browse More Trials by Condition

Cystic Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA